|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.080 USD | -2.26% |
|
-5.32% | -13.52% |
| 07-16 | Moderna advances its cancer therapy assessment, but the stock slides |  |
| 06-01 | Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMMATICS N.V. | Bio Therapeutic Drugs | -2.26% | -5.32% | -13.52% | +40.78% | -25.63% | 1.24B |  |  |  |
- Stock Market
- Stocks
- IMTX Stock
- Charts Immatics N.V.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
